76,318 Shares in Solid Biosciences Inc. $SLDB Acquired by Jump Financial LLC

Key Points

• Jump Financial LLC has acquired a new stake in Solid Biosciences Inc., purchasing 76,318 shares valued at approximately $282,000, representing 0.10% of the company's stock.
• Solid Biosciences has seen substantial interest from institutional investors, with 81.46% of its stock currently owned by such entities.
• The company recently reported earnings of ($0.42) EPS, exceeding analysts' expectations, and analysts project a price target averaging around $15.00 per share.

Jump Financial LLC bought a new stake in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 76,318 shares of the company's stock, valued at approximately $282,000. Jump Financial LLC owned approximately 0.10% of Solid Biosciences at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Wells Fargo & Company MN grew its position in Solid Biosciences by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company's stock valued at $53,000 after acquiring an additional 2,986 shares in the last quarter. Wellington Management Group LLP grew its position in Solid Biosciences by 4.0% in the 4th quarter. Wellington Management Group LLP now owns 124,551 shares of the company's stock valued at $498,000 after acquiring an additional 4,747 shares in the last quarter. American Century Companies Inc. grew its position in Solid Biosciences by 10.6% in the 1st quarter. American Century Companies Inc. now owns 51,835 shares of the company's stock valued at $192,000 after acquiring an additional 4,978 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Solid Biosciences by 8.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,607 shares of the company's stock valued at $254,000 after acquiring an additional 5,220 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Solid Biosciences by 80.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,308 shares of the company's stock valued at $57,000 after acquiring an additional 6,836 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SLDB has been the subject of several research reports. JMP Securities reaffirmed a "market outperform" rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Friday, June 6th. Piper Sandler dropped their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Chardan Capital reaffirmed a "buy" rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Thursday, August 14th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Solid Biosciences in a research note on Tuesday, June 17th. Finally, Wall Street Zen upgraded Solid Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $15.00.

Solid Biosciences Stock Performance

Shares of SLDB traded down $0.06 during midday trading on Friday, hitting $5.50. The company had a trading volume of 1,143,050 shares, compared to its average volume of 813,463. The company's 50-day simple moving average is $5.91 and its 200-day simple moving average is $4.64. The firm has a market capitalization of $428.29 million, a P/E ratio of -1.96 and a beta of 2.54. Solid Biosciences Inc. has a 1 year low of $2.41 and a 1 year high of $8.65.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.09. Equities analysts predict that Solid Biosciences Inc. will post -2.84 earnings per share for the current fiscal year.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.